New drug combo for advanced triple-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial is testing a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) for people with advanced triple-negative breast cancer. It may be an option if you have had 1 or 2 prior treatments and your cancer is not controlled by standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older
- You have triple-negative breast cancer (HR-negative, HER2-negative) that has spread in your body (locally or to other organs)
- You have received 1 or 2 prior treatments for this cancer (or it came back within a year after finishing initial therapy)
- You have at least one tumor that can be measured on scans
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
This trial tests a new combination of three drugs (camrelizumab, apatinib, and eribulin) against the standard chemotherapy chosen by your doctor. It's for people with advanced triple-negative breast cancer that has gotten worse after previous treatments.
This study tests a new drug called JSKN016 against standard chemotherapy options for triple-negative breast cancer that has stopped responding to previous treatments. The trial aims to find out if JSKN016 works better or offers other benefits for patients like you.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
This trial tests a new drug called Trastuzumab Rezetecan, either alone or combined with Bevacizumab, for people with a specific type of advanced triple-negative breast cancer that has been treated with up to two prior therapies. The goal is to see if these drugs can shrink tumors or slow cancer growth.
This study tests whether a new drug called 9MW2821 works better than standard chemotherapy for triple-negative breast cancer that has spread or cannot be removed by surgery. You would qualify if your cancer has already been treated with certain chemotherapies and your body is healthy enough to tolerate more treatment.
Hear when a new Advanced Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.